Topic: infectious disease
Aradigm’s bid to get an inhaled antibiotic to market seems at an end, with its assets up for sale and the jobs of two primary executives terminated.
Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.
The first data readout from a phase 3 trial of Scynexis’ ibrexafungerp has come in and looks very positive for the first-in-class antifungal.
Day Zero Diagnostics raised $8.6 million in series A to rapidly profile the antibiotic resistance of infectious diseases using genomic sequencing.
U.K. biotech hVIVO is on course to start a phase 3 program for a flu vaccine that doesn’t need to have its composition tweaked every year.
Brii Biosciences is expanding on existing partnerships and inking a new deal with VBI Vaccines that could be worth up to $128.5 million.
The pact tasks Weissmann’s UPenn lab with taking vaccines against up to 10 infectious diseases through to the completion of IND-enabling studies.
Qpex Biopharma launched as a new infectious disease company, simultaneously obtaining $33 million and preclinical assets from The Medicines Company.
The Chan Zuckerberg Biohub has unveiled an open-source platform for charting international infectious disease outbreaks in real time.
Insights into how bacteria hibernate and use metals to evade destruction by antibiotics could be useful in drug development.